inclusion criteria: 1. patients found to have positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging 2. male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures 4. has illness of not more than 7 days duration 5. at the time of enrolment does not require immediate resuscitation or mechanical ventilation 6. respiration rate ≤ 29 per minute 7. spo2 ≤ 95% on room air 8. agrees to not participate in another clinical trial through day 29

inclusion criteria: 1. patients found to have positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging 2. male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures 4. has illness of not more than 7 days duration 5. at the time of enrolment does not require immediate resuscitation or mechanical ventilation 6. respiration rate ≤ 29 per minute 7. spo2 ≤ 95% on room air 8. agrees to not participate in another clinical trial through day 29

inclusion criteria: patients found to have positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures subject (or legally authorized representative) understands and agrees to comply with planned study procedures has illness of not more than 7 days duration at the time of enrolment does not require immediate resuscitation or mechanical ventilation respiration rate ≤ 29 per minute spo2 ≤ 95% on room air agrees to not participate in another clinical trial through day 29

inclusion criteria: patients found to have positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures subject (or legally authorized representative) understands and agrees to comply with planned study procedures has illness of not more than 7 days duration at the time of enrolment does not require immediate resuscitation or mechanical ventilation respiration rate ≤ 29 per minute spo2 ≤ 95% on room air agrees to not participate in another clinical trial through day 29

inclusion criteria: patients found positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures subject (or legally authorized representative) understands and agrees to comply with planned study procedures has illness of not more than 7 days duration at the time of enrolment does not require immediate resuscitation or mechanical ventilation respiration rate ≤ 29 per minute spo2 ≤ 95% on room air agrees to not participate in another clinical trial through day 29

inclusion criteria: patients found positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures subject (or legally authorized representative) understands and agrees to comply with planned study procedures has illness of not more than 7 days duration at the time of enrolment does not require immediate resuscitation or mechanical ventilation respiration rate ≤ 29 per minute spo2 ≤ 95% on room air agrees to not participate in another clinical trial through day 29

inclusion criteria: 1. patients found positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging 2. male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures 4. has illness of not more than 7 days duration 5. at the time of enrolment does not require immediate resuscitation or mechanical ventilation 6. respiration rate ≤ 29 per minute 7. spo2 ≤ 95% on room air 8. agrees to not participate in another clinical trial through day 29

inclusion criteria: 1. patients found positive rt-pcr for sars-cov-2 in any specimen on 4 days prior to randomization, those who are hospitalized with evidence of respiratory disease during clinical assessment or imaging 2. male or non-pregnant female adult ≥18 years of age subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures 4. has illness of not more than 7 days duration 5. at the time of enrolment does not require immediate resuscitation or mechanical ventilation 6. respiration rate ≤ 29 per minute 7. spo2 ≤ 95% on room air 8. agrees to not participate in another clinical trial through day 29